Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Chiesi Farmaceutici S.p.A: Clinical Trials & FDA Approval Profile

Chiesi Farmaceutici S.p.A (Global / Institutional) sponsors 33 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 10 active protocols (7 recruiting now), 13 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)30.3%
Median Closed Enrollment vs National (145 pts)103 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Chiesi Farmaceutici S.p.A
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)33
Active Pipeline (Recruiting Now)10 (7)
Completed vs Stopped Early13 / 10 (30.3%)
Median Closed Actual Enrollment103 participants
Physical Hospital Site Disclosure95.9% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Chiesi Farmaceutici S.p.A
Hospital Research SiteLocationShared Protocols
Emory Winship Cancer InstituteAtlanta, GA4
Huntsman Cancer Institute at University of UtahSalt Lake City, UT3
UT Southwestern Simmons Cancer CenterDallas, TX2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Chiesi Farmaceutici S.p.A
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07516951A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary FibrosisPhase IIRECRUITING
NCT06328608A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseasePhase II/IIIRECRUITING
NCT05710692Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry DiseasePhase II/IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Chiesi Farmaceutici S.p.A Interactive Dossier, benchmark peers in Respiratory and Pulmonary, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI